|
RAD17 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.67454938804212E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.66331401377329E-12 |
| Normal-vs-Stage2 |
4.645300E-04 |
| Normal-vs-Stage3 |
2.35611530285951E-12 |
| Normal-vs-Stage4 |
1.62547753035369E-12 |
| Stage1-vs-Stage2 |
1.564830E-01 |
| Stage1-vs-Stage3 |
1.234180E-01 |
| Stage1-vs-Stage4 |
2.300900E-03 |
| Stage2-vs-Stage3 |
4.309500E-02 |
| Stage2-vs-Stage4 |
3.756900E-03 |
| Stage3-vs-Stage4 |
2.372000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.63025148935958E-12 |
| Normal-vs-AfricanAmerican |
2.38669999985675E-07 |
| Normal-vs-Asian |
3.05750003093408E-09 |
| Caucasian-vs-AfricanAmerican |
8.435000E-01 |
| Caucasian-vs-Asian |
2.912000E-01 |
| AfricanAmerican-vs-Asian |
6.463400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.56700002868138E-10 |
| Normal-vs-Female |
1.64979141459298E-12 |
| Male-vs-Female |
4.261000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.79496434277371E-12 |
| Normal-vs-Age(41-60Yrs) |
3.05533376376843E-13 |
| Normal-vs-Age(61-80Yrs) |
1.17879994654402E-09 |
| Normal-vs-Age(81-100Yrs) |
2.491200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.083600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.271400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.738000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.972600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.918800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.230400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.332190E-02 |
| Classical-VS-Follicular |
1.145370E-01 |
| Classical-VS-Other |
4.478200E-01 |
| Classical-VS-Normal |
3.25661719813297E-12 |
| Tall-VS-Follicular |
1.720490E-03 |
| Tall-VS-Other |
6.442800E-01 |
| Tall-VS-Normal |
1.28510535546411E-11 |
| Follicular-VS-Other |
3.018200E-01 |
| Follicular-VS-Normal |
2.20349999999758E-05 |
| Other-VS-Normal |
3.230300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.59749991013314E-11 |
| Normal-vs-N1 |
5.55111512312578E-16 |
| N0-vs-N1 |
2.809900E-04 |
|
|
